Dr. Amy Shapiro, MD
Claim this profileIndiana Hemophila @Thrombosis Center
Studies Hemophilia
Studies Hemophilia A
9 reported clinical trials
11 drugs studied
Area of expertise
1Hemophilia
pdFVIII
rFVIII
FFP
2Hemophilia A
pdFVIII
rFVIII
FFP
Affiliated Hospitals
Clinical Trials Amy Shapiro, MD is currently running
Natural History Study
for Blood Disorders
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)
Recruiting1 award N/A1 criteria
Hemlibra
for Mild Hemophilia A
This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) as measured by coagulation laboratory parameters in the mild hemophilia A male patient population with endogenous altered FVIII (baseline FVIII activity of \>5% to 30%). The safety and hemostatic efficacy of Hemlibra (emicizumab) in this patient population will be investigated. Secondary outcomes will assess changes in joint health and quality of life in treated patients.
Recruiting4 awards Phase 4
More about Amy Shapiro, MD
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Amy Shapiro, MD has experience with
- Emicizumab
- Liver Transplantation
- Clotting Factor Replacement Product
- Various VWF Regimens
- RFVIII
- RVWF
Breakdown of trials Amy Shapiro, MD has run
Hemophilia
Hemophilia A
Hemophilia B
Von Willebrand Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amy Shapiro, MD specialize in?
Amy Shapiro, MD focuses on Hemophilia and Hemophilia A. In particular, much of their work with Hemophilia has involved pdFVIII patients, or patients who are rFVIII.
Is Amy Shapiro, MD currently recruiting for clinical trials?
Yes, Amy Shapiro, MD is currently recruiting for 3 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Amy Shapiro, MD has studied deeply?
Yes, Amy Shapiro, MD has studied treatments such as Emicizumab, Liver Transplantation, Clotting Factor Replacement Product.
What is the best way to schedule an appointment with Amy Shapiro, MD?
Apply for one of the trials that Amy Shapiro, MD is conducting.
What is the office address of Amy Shapiro, MD?
The office of Amy Shapiro, MD is located at: Indiana Hemophila @Thrombosis Center, Indianapolis, Indiana 46260 United States. This is the address for their practice at the Indiana Hemophila @Thrombosis Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.